ClinicalTrials.gov
ClinicalTrials.gov Menu

Intravenous Metoprolol Versus Intravenous Amiodarone in the Prevention of Atrial Fibrillation After Cardiac Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00784316
Recruitment Status : Completed
First Posted : November 3, 2008
Last Update Posted : November 24, 2011
Sponsor:
Collaborators:
Tampere University Hospital
Vaasa Central Hospital, Vaasa, Finland
Information provided by (Responsible Party):
Jari Halonen, Kuopio University Hospital

Brief Summary:
The aim of the study is to test the efficiency of intravenous administration of metoprolol versus intravenous administration of amiodarone in the prevention of atrial fibrillation after cardiac surgery.

Condition or disease Intervention/treatment Phase
Atrial Fibrillation Cardiac Surgery Drug: metoprolol, amiodarone Phase 4

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 316 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Intravenous Metoprolol Versus Intravenous Amiodarone in the Prevention of Atrial Fibrillation After Cardiac Surgery
Study Start Date : August 2007
Actual Primary Completion Date : July 2009
Actual Study Completion Date : July 2009


Arm Intervention/treatment
Active Comparator: metoprolol Drug: metoprolol, amiodarone
to compare the effectiviness of intravenous administration of metoprolol and amiodarone in the prevention of atrial fibrillation after cardiac surgery

Active Comparator: amiodarone Drug: metoprolol, amiodarone
to compare the effectiviness of intravenous administration of metoprolol and amiodarone in the prevention of atrial fibrillation after cardiac surgery




Primary Outcome Measures :
  1. Incidence of atrial fibrillation [ Time Frame: 48 hours ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • elective CABG and aortic valve patients in cardiac surgery,
  • previous use of betablocker therapy

Exclusion Criteria:

  • previous atrial fibrillation or flutter,
  • thyroid disease,
  • uncontrolled heart failure,
  • II or III degree atrioventricular block

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00784316


Locations
Finland
Halonen jari
Kuopio, Finland, FIN- 70211
Sponsors and Collaborators
Kuopio University Hospital
Tampere University Hospital
Vaasa Central Hospital, Vaasa, Finland

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Jari Halonen, MD,PhD, Kuopio University Hospital
ClinicalTrials.gov Identifier: NCT00784316     History of Changes
Other Study ID Numbers: KUH5204005
First Posted: November 3, 2008    Key Record Dates
Last Update Posted: November 24, 2011
Last Verified: November 2011

Keywords provided by Jari Halonen, Kuopio University Hospital:
Prevention

Additional relevant MeSH terms:
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes
Metoprolol
Amiodarone
Anti-Arrhythmia Agents
Antihypertensive Agents
Sympatholytics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Adrenergic beta-1 Receptor Antagonists
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Vasodilator Agents
Potassium Channel Blockers
Membrane Transport Modulators
Sodium Channel Blockers
Cytochrome P-450 CYP1A2 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors
Cytochrome P-450 CYP2C9 Inhibitors
Cytochrome P-450 CYP2D6 Inhibitors
Cytochrome P-450 CYP3A Inhibitors